Captopril and hydrochlorothiazide tablets have been tentatively approved for the treatment of hypertension. Tablets will be manufactured in 25mg/15mg, 50mg/15mg, 25mg/25mg and 50mg/25mg strengths. This antihypertensive product is the generic equivalent of Bristol-Myers Squibb’s capozide. Shipment is scheduled to begin after the Dec. 27, 1997 expiration of Bristol-Myers Squibb’s patent.
The Captopril and hydrochlorotiazide drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.